Features of cardiac remodeling and GDF 15 and NTproBNP levels in patients with heart failure and preserved ejection fraction depending on the history of myocardial infarction

Authors

DOI:

https://doi.org/10.14739/2310-1210.2024.5.309424

Keywords:

heart failure, myocardial infarction, cardiac biomarkers, cardiac remodeling

Abstract

Aim. To determine the relationships between serum concentrations of growth and differentiation factor 15 (GDF 15) and NTproBNP and features of heart remodeling in patients with heart failure and preserved ejection fraction (HFPEF) depending on the history of Q-myocardial infarction (MI).

Materials and methods. The study was performed on the basis of the Cardiology Department of the Municipal non-profit Enterprise “City Hospital of Urgent and Emergency Medical Care” of Zaporizhzhia City Council. 72 patients (mean age 62.1 ± 1.7 years) with HFPEF after MI were enrolled. The patients were divided into two groups depending on the time of previous MI. The patients were examined using two-dimensional echocardiography on a MyLab50 device (Esaote, Italy) according to the recommendations of the American Society of Echocardiography. Serum concentrations of GDF 15 and NTproBNP were measured by enzyme immunoassay using Elabscience reagent kits (USA).

Results. In the 1st and 2nd groups of patients who suffered MI within a year, a significant increase in GDF 15 has been found (by 66.1 % and 74.7 %, respectively; p < 0.05) compared to the control group. The level of GDF 15 was significantly higher (by 41.8 %, p < 0.05) in the group of patients who had MI over a one-to-two-year period as compared to those who had MI within one year. The serum concentration of NTproBNP was also significantly higher in HFPEF groups compared to the control group (by 84.7 % and 87.2 %, respectively, p < 0.05). In the 2nd group of patients with the history of MI between 1 and 2 years, a significant increase in end-systolic volume (by 11.8 %, p < 0.05), end-diastolic volume (by 22.3 %, p < 0.05), left ventricular myocardial mass index (by 19.1 %, p < 0.05) and the E/e’ ratio (by 20.9 %, p < 0.05) has been revealed as compared to the 1st patient group. A strong direct correlation has been shown between the time of MI occurrence and the concentration of GDF 15 (r = 0.58, p < 0.05), the interventricular septum thickness at diastole (r = 0.61, p < 0.05) and the left ventricular myocardial mass index (r = 0.63, p < 0.05), GDF 15 and E/e’ (r = 0.37, p < 0.05), GDF 15 and the left atrial volume index (r = 0.41, p < 0.05), GDF 15 and NTproBNP (r = 0.56, p < 0.05).

Conclusions. Progression of left ventricular myocardial hypertrophy and diastolic dysfunction with dilatation of the heart chambers has been observed in HFPEF patients with a longer history of MI. The time period of MI in patients with HFPEF was associated with the serum concentration of GDF 15, the interventricular septum thickness and the mass index of the left ventricular myocardium. The serum concentration of GDF 15 was significantly correlated with the deterioration of the left ventricular diastolic function, such as an increase in the E/e’ ratio and the left atrial volume index.

Author Biographies

Ya. V. Zemlianyi, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Internal Diseases 1

N. A. Zemliana, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Assistant of the Department of Obstetrics and Gynecology

References

Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021:S1071-9164(21)00050-6. doi: https://doi.org/10.1016/j.cardfail.2021.01.022

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(48):4901. doi: https://doi.org/10.1093/eurheartj/ehab670

Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254-e743. doi: https://doi.org/10.1161/CIR.0000000000000950

Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559-73. doi: https://doi.org/10.1038/s41569-020-0363-2

Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698-717. doi: https://doi.org/10.1038/s41569-020-0381-0

Du H, Yang L, Zhang H, Zhang XL, Shao HY. Correlation between growth differentiation factor-15 and the severity of chronic heart failure in patients with coronary atherosclerosis. Eur Rev Med Pharmacol Sci. 2020;24(24):12844-8. doi: https://doi.org/10.26355/eurrev_202012_24186

Li M, Duan L, Cai YL, Li HY, Hao BC, Chen JQ, et al. Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020;19(1):120. doi: https://doi.org/10.1186/s12933-020-01092-7

Meessen JM, Cesaroni G, Mureddu GF, Boccanelli A, Wienhues-Thelen UH, Kastner P, et al. PREDICTOR Investigators. IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study. BMC Cardiovasc Disord. 2021;21(1):328. doi: https://doi.org/10.1186/s12872-021-02138-8

Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2016 Jan;18(1):81-8. doi: https://doi.org/10.1002/ejhf.431

Rabkin SW, Tang JK. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Heart Fail Rev. 2021;26(4):799-812. doi: https://doi.org/10.1007/s10741-020-09913-3

Sabry AS, El-Rabat K, Attia A, Abd El-Fatah H. Left ventricular remodeling in patients with primary percutaneous coronary intervention for anterior myocardial infarction. Benha Medical Journal. 2020;0(0). https://doi.org/10.21608/bmfj.2020.112400

Reindl M, Reinstadler SJ, Tiller C, Feistritzer HJ, Kofler M, Brix A, et al. Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction. Eur Radiol. 2019;29(5):2330-9. doi: https://doi.org/10.1007/s00330-018-5875-3

Abou R, Goedemans L, Montero-Cabezas JM, Prihadi EA, El Mahdiui M, Schalij MJ, et al. Prognostic Value of Multilayer Left Ventricular Global Longitudinal Strain in Patients with ST-segment Elevation Myocardial Infarction with Mildly Reduced Left Ventricular Ejection Fractions. Am J Cardiol. 2021;152:11-8. doi: https://doi.org/10.1016/j.amjcard.2021.04.033

Chimed S., van Der Bijl P, Lustosa R, Montero JM, Marsan NA, Delgado V, et al. Left ventricular remodelling pattern and prognostic relevance in patients with STEMI treated with primary percutaneous coronary intervention. Eur Heart J. 2020;41(Suppl 2):ehaa946.0910. doi: https://doi.org/10.1093/ehjci/ehaa946.0910

Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017;63(1):140-51. doi: https://doi.org/10.1373/clinchem.2016.255174

Downloads

Additional Files

Published

2024-10-04

How to Cite

1.
Zemlianyi YV, Zemliana NA. Features of cardiac remodeling and GDF 15 and NTproBNP levels in patients with heart failure and preserved ejection fraction depending on the history of myocardial infarction. Zaporozhye Medical Journal [Internet]. 2024Oct.4 [cited 2024Nov.22];26(5):366-70. Available from: http://zmj.zsmu.edu.ua/article/view/309424

Issue

Vol. 26 No. 5 (2024): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)